Financing channel feed – Endpoints News

Financing channel feed

'We want to be everywhere.' Mission Bio raises $70M behind resistance-hunting sequencing platform

5 years ago

On the heels of a snap $1B raise, CureVac outlines plans to seek emergency OK for Covid-19 vaccine -- shares rocket up

5 years ago

CanSino reaps $748M windfall from Shanghai IPO — as it warns Covid-19 vaccine won't be a huge money maker

5 years ago

Novo backs 'breakthrough' antifungal player's $60M round — with a focus on rare mold infections

5 years ago

Plotting to be the BridgeBio of AI, Atomwise lands $123 million Series B for hype-heavy platform

5 years ago

Vida Ventures co-leads Dyne's $115M megaround for next-gen oligo therapies aimed squarely at muscles

5 years ago

Versant funds TCR therapy biotech T-knife's $78M+ Series A to boost humanized T cell mice platform

5 years ago

RA, Novartis back GentiBio's seed round, plans to launch development of EngTreg therapies

5 years ago

Less than 3 months after launch, the AveXis crew’s Taysha raises $95M Series B. Is an IPO next?

5 years ago

Versant debuts Ridgeline's startup #4, armed with $30M and alternative TCR cell therapies for solid tumors

5 years ago

CF Foundation, Longwood team on new incubator for companies with cutting-edge CF treatments

5 years ago

Deep tech, round 2: DCVC Bio bags $350M fund to chase the tip of the life science spear

5 years ago

IgGenix emerges from stealth with $10 million Series A hoping to re-engineer allergic cascade

5 years ago

Rich Heyman joins PMV Pharma, a p53 biotech, as it adds $70 million in Series D

5 years ago

Days after sealing Sanofi pact, Kymera beats a path to the Nasdaq with $100M IPO pitch

5 years ago

AlloVir rides IPO boom on first market day, soars after bagging $276 million

5 years ago

Adding $445M, Tony Coles and his big Pfizer neuro spinout hitch a ride to Wall Street on Perceptive’s SPAC

5 years ago

Codiak gets a competitor, as Mantra Bio leaves stealth and enters growing exosome space

5 years ago

'Exquisite control': Flagship pulls off $85M rally around Omega Therapeutics' clinical push for epigenetic programming tech

5 years ago

Three years after leaving Biogen, Alpna Seth takes the spotlight with $73M for her neuro startup

5 years ago

Inhibrx takes a second shot at an IPO — this time bumping the goal to $100M-plus

5 years ago

Test results in hand, Thrive raises $257M to push liquid biopsy toward approval

5 years ago

Praxis raises $110 million to target CNS disease with Phase II drugs

5 years ago

Distanced from a pricing controversy, Jeff Aronin steers one of his biotechs to Nasdaq — with a familiar regulatory strategy tied to a big bet

5 years ago

First page Previous page 93 94 959697 98 99 Next page Last page